A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

Adenoviruses are attractive vectors for the delivery of foreign genes into mammalian cells for gene therapy. However, current vectors retain many viral genes that, when expressed at low levels, contribute to the induction of a host immune response against transduced cells. We have developed a helper-dependent packaging system for production of vectors that have large regions of the genome deleted. Helper viruses were constructed with packaging signals flanked by loxP sites so that in 293 cells that stably express the Cre recombinase (293Cre), the packaging signal was efficiently excised, rendering the helper virus genome unpackageable. However, the helper virus DNA was replicated at normal levels and could thus express all of the functions necessary in trans for replication and packaging of a vector genome containing the appropriate cis-acting elements. Serial passage of the vector in helper virus-infected 293Cre cells resulted in an approximately 10-fold increase in vector titer per passage. The vector could be partially separated from residual helper virus by cesium chloride buoyant density centrifugation. Large scale preparations of vector yielded semi-purified stocks of approximately 10(10) transducing virions/ml, with < 0.01% contamination by the E1-deleted helper virus. This system should have great utility for the generation of adenovirus-based vectors with increased cloning capacity, increased safety and reduced immunogenicity.

[1]  C. Caskey,et al.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Luthra,et al.  Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy , 1996, Journal of virology.

[3]  J. Chamberlain,et al.  Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Wilson,et al.  Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. , 1996, Virology.

[5]  R. Frizzell,et al.  Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. , 1996, Human gene therapy.

[6]  M. Perricaudet,et al.  Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit , 1996, Journal of virology.

[7]  F. Graham,et al.  Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. , 1995, Human gene therapy.

[8]  F. Graham,et al.  An adenoviral vector expressing interleukin-4 modulates tumorigenicity and induces regression in a murine breast-cancer model. , 1995, International Journal of Oncology.

[9]  G. Prince,et al.  Characterization of an adenovirus gene transfer vector containing an E4 deletion. , 1995, Human gene therapy.

[10]  W. Muller,et al.  Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Graham,et al.  Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression , 1995, Journal of virology.

[12]  J. Schaack,et al.  Adenovirus type 5 precursor terminal protein-expressing 293 and HeLa cell lines , 1995, Journal of virology.

[13]  J. Wilson,et al.  Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. , 1995, Human gene therapy.

[14]  C. Caskey,et al.  Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Hitt,et al.  [2] Techniques for human adenovirus vector construction and characterization , 1995 .

[16]  F. Graham,et al.  The use of adenoviral vectors for gene therapy and gene transfer in vivo. , 1995, Current opinion in biotechnology.

[17]  Hanns Lochmüller,et al.  Emergence of Early Region 1-Containing Replication-Competent Adenovirus in Stocks of Replication-Defective Adenovirus Recombinants (ΔE1 + ΔE3) During Multiple Passages in 293 Cells , 1994 .

[18]  R. Crystal,et al.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis , 1994, Nature Genetics.

[19]  James M. Wilson,et al.  Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis , 1994, Nature Genetics.

[20]  J. Wilson,et al.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Whitsett,et al.  In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. , 1994, Human gene therapy.

[22]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Crystal,et al.  Adenovirus‐Mediated in Vivo Gene Transfer , 1994, Annals of the New York Academy of Sciences.

[24]  J. Wilson,et al.  Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. , 1993, Human gene therapy.

[25]  Joseph Zabner,et al.  Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis , 1993, Cell.

[26]  F. Graham,et al.  Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.

[27]  P. Hearing,et al.  cis and trans requirements for the selective packaging of adenovirus type 5 DNA , 1992, Journal of virology.

[28]  M. Perricaudet,et al.  In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium , 1992, Cell.

[29]  M. Hitt,et al.  Isolation and characterization of insertion mutants in E1A of adenovirus type 5. , 1991, Virology.

[30]  H. Sambrook.  Molecular cloning : a laboratory manual. Cold Spring Harbor, NY , 1989 .

[31]  K. Wood,et al.  Firefly luciferase gene: structure and expression in mammalian cells , 1987, Molecular and cellular biology.

[32]  F. Graham.  Covalently closed circles of human adenovirus DNA are infectious. , 1984, The EMBO journal.

[33]  D. Solnick.  Construction of an adenovirus-SV40 recombinant producing SV40 T antigen from an adenovirus late promoter , 1981, Cell.

[34]  R. Tjian,et al.  Expression of SV40 T antigen under control of adenovirus promoters , 1981, Cell.

[35]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[36]  E. Southern.  Detection of specific sequences among DNA fragments separated by gel electrophoresis. , 1975, Journal of molecular biology.

[37]  U. Schibler,et al.  Changes in size and secondary structure of the ribosomal transcription unit during vertebrate evolution. , 1975, Journal of molecular biology.

[38]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.